We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$76M
AUM Growth
-$11.1M
Cap. Flow
+$112M
Cap. Flow %
147.28%
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131

Sector Composition

Rank Sector Weight
1 Healthcare 34.66%
2 Consumer Staples 16.16%
3 Consumer Discretionary 9.31%
4 Communication Services 3.38%
5 Materials 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALR
401
CALL
DELISTED
Alere Inc
ALR
-9,500
Closed -$44K
ALR
402
DELISTED
Alere Inc
ALR
-500
Closed -$19K
PNRA
403
DELISTED
Panera Bread Co
PNRA
-6,243
Closed -$1.42M
SE
404
DELISTED
Spectra Energy Corp Wi
SE
-24,150
Closed -$992K
SE
405
PUT
DELISTED
Spectra Energy Corp Wi
SE
-30,000
Closed -$108K
STJ
406
CALL
DELISTED
St Jude Medical
STJ
-28,400
Closed -$10K
TACO
407
CALL
DELISTED
Del Taco Restaurants, Inc. Common Stock
TACO
-56,600
Closed -$9K
TACO
408
PUT
DELISTED
Del Taco Restaurants, Inc. Common Stock
TACO
-10,000
Closed -$10K

Similar funds

FT Options's Q1 2017 Portfolio in Review

As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

FT Options deployed $112M of net new capital in Q1 2017, opening 159 new positions and adding to 53 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $9.7M trimmed.

  • FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
  • FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
  • FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
  • FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
  • FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
  • FT Options opened 159 new positions and closed 131 in Q1 2017.
  • FT Options's portfolio value fell 13% quarter-over-quarter to $76M.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.